evt_e0b0f7d5-a24a-5a54-9190-887426002bf9Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
phase3_result
evd_0924c835-a5c7-51fe-898a-4df668a7bf16, evd_3133b426-7ea3-5095-a35f-578418c1f88f, evd_4cf047a5-a90e-5e60-991a-b1db3231600f, evd_6c9b1bda-8327-5f65-bfb5-1369186ab283, evd_96e2a8a7-b929-5db5-8ed9-c81cde43ca86, evd_caea34ef-7e74-53e1-aa44-f9ff8cf123a9, evd_e778933e-baf4-54b6-80b0-baa12180ad31, evd_e882a522-6f22-50b6-a01e-9991285d8ba9fact_c78b258e-24b8-5823-8abd-df76cdb51c30, fact_c9e71c02-0823-5c7d-bb44-9bd6697726a1, fact_daa7c8fd-1c5f-5eac-bf44-b27ef05de897rel_30def33f-c66f-5cd0-b3b2-59d58041f69b, rel_588e3737-52f2-54df-b28a-39554ee0c7e1, rel_65959a56-b590-57a0-8691-e131ee821541, rel_ddc780fb-cb03-5948-b52d-f2db7f7beac0